Advancing Aminoadamantane-based Therapeutics for CNS Disorders

Adamas Pharmaceuticals is the leading developer of aminoadamantane-based therapeutics. The Company’s products are designed to be better tolerated, more effective and easier-to-use formulations. The two lead product candidates include Arimenda™ (ADS-8704), the first potential fixed dose combination drug treatment for Alzheimer’s, and Nurelin™ (ADS-5102) the first potential drug labeled for the treatment of Levodopa-induced dyskinesia in Parkinson’s disease.